Relmada Therapeutics To Report Second Quarter 2024 Financial Results On August 7, 2024

2024-08-05 07:46:57

(MENAFN- GlobeNewsWire - Nasdaq) CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD,“Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Conference Call and Webcast Information:
Date: Wednesday, August 7, 2024 at 4:30 PM ET
Participant Dial-in (US): 1-800-717-1738
Participant Dial-in (International): 1-646-307-1865
Conference: 39584
Webcast Access: Click Here

The conference call utilizes the“Call meTM” technology

Participants can use Guest dial-in #s above and be answered by an operator OR click the Call meTM link, above, for instant telephone access to the event.
Call meTM link will be made active 15 minutes prior to scheduled start time.

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at .

Investor Contact:
Tim McCarthy
LifeSci Advisors
...

MENAFN05082024004107003653ID1108517640

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.